Palantir stock plunges on NHS business risk

Palantir stock plunged on June 9, 2022, following a Reuters report that the UK government initiated a formal review of its £330 million NHS contract with Palantir. This review, driven by concerns over data privacy and security, could potentially end the five-year contract, representing a significant loss for Palantir.

The review has triggered a sell-off in Palantir's stock, which has lost roughly half its value. The tech sector, particularly data analytics and AI stocks, is affected, as investors reassess Palantir's growth prospects and valuation. The broader market is also watching, as the review raises questions about government contracts and data privacy, which could impact other tech companies.

Investors should watch for the UK government's final decision on the NHS contract by Q3 2022. Additionally, Palantir's Q2 2022 earnings report, scheduled for August 11, will provide insights into the company's financial health and growth prospects amidst this uncertainty.